A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin's lymphoma (NHL). Everolimus is an oral agent that targets the raptor mammalian target of rapamycin (mTORC1). The goal of this trial was to learn the antitum...

Descripción completa

Detalles Bibliográficos
Autores principales: Witzig, T E, Reeder, C B, LaPlant, B R, Gupta, M, Johnston, P B, Micallef, I N, Porrata, L F, Ansell, S M, Colgan, J P, Jacobsen, E D, Ghobrial, I M, Habermann, T M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049870/
https://www.ncbi.nlm.nih.gov/pubmed/21135857
http://dx.doi.org/10.1038/leu.2010.226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049870/
https://www.ncbi.nlm.nih.gov/pubmed/21135857
http://dx.doi.org/10.1038/leu.2010.226

Ejemplares similares